TW201618785A - 使用ｅｒｋ抑制劑的治療方法 - Google Patents

使用ｅｒｋ抑制劑的治療方法 Download PDF

Info

Publication number
TW201618785A
TW201618785A TW104126315A TW104126315A TW201618785A TW 201618785 A TW201618785 A TW 201618785A TW 104126315 A TW104126315 A TW 104126315A TW 104126315 A TW104126315 A TW 104126315A TW 201618785 A TW201618785 A TW 201618785A
Authority
TW
Taiwan
Prior art keywords
cancer
compound
mutant
melanoma
braf
Prior art date
Application number
TW104126315A
Other languages
English (en)
Chinese (zh)
Inventor
高登Ｌ 布雷
艾倫Ｈ 菲瓦洛夫
Original Assignee
西建阿維拉米斯研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 西建阿維拉米斯研究公司 filed Critical 西建阿維拉米斯研究公司
Publication of TW201618785A publication Critical patent/TW201618785A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104126315A 2014-08-13 2015-08-12 使用ｅｒｋ抑制劑的治療方法 TW201618785A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037091P 2014-08-13 2014-08-13

Publications (1)

Publication Number Publication Date
TW201618785A true TW201618785A (zh) 2016-06-01

Family

ID=55304588

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104126315A TW201618785A (zh) 2014-08-13 2015-08-12 使用ｅｒｋ抑制劑的治療方法

Country Status (2)

Country Link
TW (1) TW201618785A (fr)
WO (1) WO2016025621A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046696A1 (en) * 2017-02-14 2020-02-13 Celgene Corporation Treatment of cancer with smg1-inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360970B (es) * 2008-06-27 2018-11-23 Avila Therapeutics Inc Compuestos de heteroarilo y usos de los mismos.
CN106831732B (zh) * 2011-06-10 2019-12-24 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法

Also Published As

Publication number Publication date
WO2016025621A1 (fr) 2016-02-18

Similar Documents

Publication Publication Date Title
ES2905915T3 (es) Procedimientos de tratamiento de neoplasias malignas
EP3419593B1 (fr) Énasidénib destiné au traitement de la leucémie myéloïde aiguë récidivante ou réfractaire
CN108601787B (zh) 用于治疗恶性肿瘤的组合疗法
ES2620644T3 (es) Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
EP3493809B1 (fr) Enasidenib pour le traitement du syndrome myélodysplasique
SG188207A1 (en) Combination anti - cancer therapy
JP6995058B2 (ja) （１ｓ，４ｓ）－４－（２－（（（３ｓ，４ｒ）－３－フルオロテトラヒドロ－２ｈ－ピラン－４－イル）アミノ）－８－（（２，４，６－トリクロロフェニル）アミノ）－９ｈ－プリン－９－イル）－１－メチルクロロヘキサン－１－カルボキサミドの固体形態及びその使用方法
WO2019045036A1 (fr) Inhibiteur sélectif de l'egfr muté sur l'exon 18 et/ou sur l'exon 21
KR20120099219A (ko) 조합물
KR20210126654A (ko) 암 치료
TW201618785A (zh) 使用ｅｒｋ抑制劑的治療方法
TW202342047A (zh) 使用經取代之嘧啶-4(3h)-酮及索托拉西布(sotorasib)之組合療法
TWI554502B (zh) 受體型激酶調節劑及治療多囊性腎疾病的方法
JP7093764B2 (ja) 骨髄異形成症候群の治療方法
WO2022163794A1 (fr) Composition de médicament pour le traitement de cancers pédiatriques
TW202339748A (zh) 使用經取代之嘧啶-4(3h)-酮之治療方法
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
CN117043159A (zh) Kras突变型癌症的治疗
WO2024091551A1 (fr) Formes cristallines, compositions pharmaceutiques et leurs procédés d'utilisation
KR20240009465A (ko) 진행성 고형 종양의 치료를 위한 fgfr 티로신 키나제 억제제